Compare CORT & XP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CORT | XP |
|---|---|---|
| Founded | 1998 | 2001 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.4B |
| IPO Year | 2001 | 2019 |
| Metric | CORT | XP |
|---|---|---|
| Price | $117.17 | $15.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $96.50 | $23.17 |
| AVG Volume (30 Days) | 1.2M | ★ 3.5M |
| Earning Date | 04-30-2026 | 05-19-2026 |
| Dividend Yield | N/A | ★ 0.98% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $761,407,000.00 | N/A |
| Revenue This Year | $26.08 | $19.00 |
| Revenue Next Year | $26.98 | $13.64 |
| P/E Ratio | $1,271.89 | ★ $11.42 |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $28.66 | $14.80 |
| 52 Week High | $122.21 | $23.13 |
| Indicator | CORT | XP |
|---|---|---|
| Relative Strength Index (RSI) | 66.55 | 39.06 |
| Support Level | $76.41 | $14.97 |
| Resistance Level | $122.21 | $17.22 |
| Average True Range (ATR) | 5.00 | 0.53 |
| MACD | -0.00 | -0.14 |
| Stochastic Oscillator | 81.48 | 10.07 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission. Geographically, the company derives maximum revenue from Brazil and also has its presence in other countries.